Happy Monday! Secretary Kennedy’s Hill-a-Thon may have come to a close, but Congress isn’t slowing down. This week, lawmakers will engage with health system CEOs, examine proposals related to food regulation and oversight, revisit questions around COVID-19 vaccine safety, and review funding for the Indian Health Service. These discussions come as the administration continues to advance its priorities on drug pricing and behavioral health, contributing to an increasingly active and complex policy landscape. Here are the key developments shaping the week ahead.

In this week’s Nimitz Health:

• Federal News: Most Favored Nation agreements, psychedelic therapies and behavioral health initiatives, Congressional oversight of HHS and vaccine policy

• State News: Florida KidCare implementation delays, Medicaid and CHIP coverage requirements

• Industry News: Health care lobbying trends, drug pricing pressures and uncertainty, emerging opportunities in behavioral health innovation

WHO’S HAVING EVENTS THIS WEEK?

Tuesday, April 28th

• *House Ways and Means: “Full Committee Hearing with Health System CEOs” at 10:00 am. Watch here.

Wednesday, April 29th

• House Energy and Commerce Subcommittee on Health: “Healthier America: Legislative Proposals on the Regulation and Oversight of Food” at 2 pm. Watch here.

• Senate Homeland Security and Governmental Affairs Permanent Subcommittee on Investigations: “Hearings to examine Biden Health Officials and COVID-19 Vaccine Safety Signals” at 2:30 pm. Watch here.

Thursday, April 30th

• House Appropriations Subcommittee on Interior, Environment, and Related Agencies: “Budget Hearing – Indian Health Service” at 10:30 am. Watch here.

*Will be covered by Nimitz Health. Please email [email protected] if you would like a readout of any other hearings.

Sign up for The Nimitz Report for Veteran Health-Related Hearings

NEWS DRIVING THE WEEK

Federal News

The Trump administration continues to aggressively reshape federal health policy, with a particular focus on drug pricing and behavioral health innovation. Last week, the White House announced another “most-favored-nation” pricing agreement, this time with Regeneron, underscoring a continued push to tie U.S. drug prices to international benchmarks. At the same time, CMS extended Medicare’s temporary GLP-1 obesity drug Bridge coverage program, maintaining access for seniors while leaving long-term coverage policy unresolved.

Behavioral health policy is quickly emerging as a central pillar of the administration’s agenda. Following President Trump’s April 18 executive order, the FDA moved within days to accelerate development of psychedelic-based therapies, prioritizing treatments for conditions like PTSD, treatment-resistant depression, and substance use disorders. The agency is issuing priority review vouchers and allowing new clinical trials, including the first U.S. study of an ibogaine derivative, signaling a meaningful shift in federal openness to these therapies.

Congressional scrutiny of HHS Secretary Robert F. Kennedy Jr. also intensified as he returned to Capitol Hill for a series of high-profile hearings tied to the FY2027 budget. Senate HELP Committee leaders, particularly Sen. Bill Cassidy, continued to challenge Kennedy on vaccine confidence and outbreak preparedness, while internal GOP divisions are surfacing around key nominations and broader MAHA-aligned policies. Lawmakers from both parties pressed Kennedy on vaccine policy, affordability, and the broader direction of the administration’s health agenda, reflecting ongoing tension between MAHA priorities and traditional public health frameworks.

Budget reconciliation negotiations are also beginning to pull health policy back into focus. Early indications suggest Republican leaders are pursuing a narrower package, but debates over abortion policy and Medicaid funding, including the potential for Planned Parenthood funding changes, remain unresolved and could reshape the final scope of health provisions.

State News

At the state level, Florida is emerging as a key battleground over children’s coverage policy. The state continues to delay implementation of its KidCare expansion, despite legislative approval, while also resisting a federal requirement to provide 12 months of continuous Medicaid and CHIP coverage for children. This makes Florida an outlier nationally and raises concerns about coverage losses tied to administrative churn.

The implications are significant. Florida has one of the largest populations of uninsured children in the country, and the delay in expanding eligibility to 300 percent of the federal poverty level could prolong coverage gaps for hundreds of thousands of children. The dispute also highlights broader federal-state tensions over Medicaid flexibility and administrative requirements.

Industry News

Health care stakeholders are ramping up engagement in Washington as policy volatility increases. Lobbying activity across insurers, providers, and pharmaceutical companies remains elevated, with industry groups working to influence a rapidly evolving landscape shaped by drug pricing pressure, MAHA priorities, and regulatory shifts.

For the life sciences sector, the administration’s approach is becoming clearer. On one hand, drugmakers face continued pricing pressure through federal negotiation tactics and public scrutiny. On the other hand, new opportunities are emerging through accelerated FDA pathways and federal investment in behavioral health innovation. The administration’s push on psychedelic therapies, coupled with ARPA-H funding and regulatory prioritization, is expected to catalyze activity across biotech, digital therapeutics, and mental health-focused startups.

FOR FUN

Want to travel the world without leaving DC this weekend? Check out Embassy Day!

JOIN THE NIMITZ NETWORK!

Enjoying our updates? Don’t keep it to yourself — forward this email to friends or colleagues who’d love to stay informed. Please subscribe to our other publications by clicking below: